NUS Links:
A/Prof Takaomi Sanda, Dr Lim Fang Qi and team have shown how PIK-75, a drug dismissed over 10 years ago, is proving vital in treating aggressive blood cancer, especially in
CanCycle 2023 is now in full swing! Thank you for all your support thus far 🙂 Read on to find more about the people you’d be making a difference to.
N2CR member, A/Prof Too Heng-Phon, Dr Sarah Ho and team have developed a way to use stem cells to treat cancer in cats and dogs, a method originally developed for
Precision Cancer Medicine thematic member, Dr Yong Wei Peng was part of a team who developed an antibody-drug conjugate (ADC), the first of its kind to be created in Singapore.
A/Prof Koh Liang Piu, member of the N2CR Tissue-Specific Carcinogenesis theme, helped to develop a cell selection technique that gives blood cancer patients a higher chance of finding a match
(image credit: The Straits Times) For the past two decades, Prof Too has played a tremendous role in strengthening life sciences research and development in Singapore. His steadfast dedication
Every year, analytics company Clarivate publishes a list of highly cited researchers who have constantly produced high impact research and published multiple highly cited papers in the last decade. This
Every year Stanford University publishes a list of highly cited scientists based on citation metrics from Scopus. The list for the citation year 2021 is accessible here: https://elsevier.digitalcommonsdata.com/datasets/btchxktzyw/4 A huge
N2CR member Associate Professor Too Heng-Phon, who co-foundered biotech firm MiRXES with two of his former PhD students, Dr Zhou Lihan and Dr Zhou Ruiyang, has developed a test kit
N2CR members, A/Prof Edward Chow and Dr Anand Jeyasekharan have found a method to create a more personalized combination of drugs for their cancer patients. Both doctors, who are principal